Search clinical trials for: Amikacin Inhalation Solution (BAY41-6551)

Total 236 results

Bayer
Nektar Therapeutics

Completed

Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia

Pneumonia

United States, France
Bayer
Nektar Therapeutics

Completed

Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia (INHALE 1)

Pneumonia, Bacterial

Korea, Republic of, Taiwan, United States, Canada, Philippines, Turkey, Thailand, Australia, Mexico, Colombia, Czechia, Brazil
Bayer
Nektar Therapeutics

Completed

A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)

Pneumonia

France, Spain, United States
Cardeas Pharma

Withdrawn

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization

Pneumonia, Bacterial
Cardeas Pharma

Completed

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia (IASIS)

Pneumonia, Bacterial

Spain, United States, Greece, Hungary, Turkey, Puerto Rico, France
Insmed Incorporated

Completed

A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants

Healthy Volunteers
University Hospital St Luc, Brussels
Université Catholique de Louvain; University of Applied Sciences of Western... and other collaborators

Completed

In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation (Synchro-Neb)

Lung Diseases | Asthma | Cystic Fibrosis | COPD | Respiratory Diseases

Belgium
Insmed Incorporated

Withdrawn

Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Cystic Fibrosis
Insmed Incorporated
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

Mycobacterium Infections, Nontuberculous

United States, Canada
University Medical Center Groningen

Recruiting

Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™

Tuberculosis

Netherlands
Insmed Incorporated

Completed

Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone (CONVERT)

Mycobacterium Infections, Nontuberculous
Insmed Incorporated

Completed

Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Pseudomonas Aeruginosa Infection

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Denmark, Greece, Canada, Netherlands, Hungary, Italy, Ireland, Sweden, Slovakia, Austria, Serbia
Insmed Incorporated

Completed

Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Cystic Fibrosis

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Serbia, Denmark, Greece, Netherlands, Hungary, Ireland, Slovakia, Canada, Italy, Austria
Insmed Incorporated

Completed

Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase

Cystic Fibrosis

Poland, Ukraine, Serbia, Belgium, Hungary, Slovakia, North Macedonia
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

Plaque Psoriasis

United States
Insmed Incorporated

Completed

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)

Cystic Fibrosis

Poland, Ukraine, Serbia, Belgium, Hungary, Slovakia, North Macedonia
Aires Pharmaceuticals, Inc.

Completed

Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers (AIR001-CS02)

Pulmonary Arterial Hypertension

United States
Pharmosa Biopharm Inc.
PPD

Completed

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

Pulmonary Arterial Hypertension

United States
Insmed Incorporated

Completed

Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

NTM Lung Infection Due to MAC
Othera Pharmaceuticals

Terminated

Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal

Epiretinal Membrane | Macular Hole

United States
Association Pour La Promotion A Tours De La Reanimation...

Unknown

Pharmacokinetics of Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation (DARTAGNAN)

Ventilator Associated Pneumonia

France
Aires Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States
Pharmosa Biopharm Inc.
Novotech (Australia) Pty Limited

Recruiting

Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults

Pulmonary Arterial Hypertension

Australia
Mylan Pharma UK Ltd.

Completed

Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

COPD

China
Aires Pharmaceuticals, Inc.

Terminated

A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, Australia, Hungary
National Jewish Health

Unknown

Use of DNAse in Neutrophilic Asthma

Neutrophilic Asthma

United States
Meiji Seika Pharma Co., Ltd.

Completed

Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers

Healthy

United States
Erik Allen Jensen
University of Florida

Active, not recruiting

Inhaled Tobramycin in BPD

Bronchopulmonary Dysplasia

United States
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Insmed Incorporated

Completed

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (ARISE)

Mycobacterium Infections, Nontuberculous

United States, Argentina, Australia, Austria, Canada, Chile, Denmark, Germany, Israel, Italy, Korea, Republic of, New Zealand, Spain, Taiwan
Bitop AG

Active, not recruiting

Multicentre Post-market Study of Ectoin® Inhalation Solution in Treatment of Asthma. (EIL-AST)

Asthma

Poland
Bitop AG

Completed

Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung (EFECT)

COPD | Particulate Matter Induced Inflammation of the Lung

Germany
Gerard Turino

Completed

Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency

Emphysema | Alpha 1-Antitrypsin Deficiency

United States, Canada
Mylan Pharma UK Ltd.

Completed

Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution

Healthy Volunteers Bioavailability Study

China
Merck Sharp & Dohme LLC

Terminated

Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642) (DEFY)

Cystic Fibrosis
Arrowhead Pharmaceuticals

Recruiting

Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Denmark, New Zealand, Spain
Merck Sharp & Dohme LLC

Terminated

Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease

Cystic Fibrosis
Insmed Incorporated

Completed

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Bronchiectasis

United States, United Kingdom, Bulgaria, India, Serbia, Ukraine, Greece, Hungary, Poland
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

Phase Ia Study of XW001 in Healthy Adult Subjects

Respiratory Syncytial Virus Infections

China
University College, London

Completed

Nebulised Dornase Alfa for Treatment of COVID-19 (COVASE)

Hypoxia | COVID19

United Kingdom
University of Missouri-Columbia

Completed

Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) (DORNASESARS2)

SARS-CoV 2 | ARDS

United States
Spyryx Biosciences, Inc.

Completed

An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis ((HOPE-1))

Cystic Fibrosis

United Kingdom, Canada, France, Italy, Portugal
GlaxoSmithKline

Completed

GSK573719 IV Enabling Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study in Adult and Pediatric Patients With Cystic Fibrosis

Cystic Fibrosis
Kexing Biopharm Co., Ltd.

Recruiting

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

Respiratory Syncytial Virus Infections

China
Zhejiang Echon Biopharm Limited

Active, not recruiting

Phase I Clinical Study of GB002 Recombinant Peptide Inhalation Solution

Healthy

China
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE)

Acute Viral Bronchiolitis

France
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC

Completed

Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease

Cystic Fibrosis

United States, Australia, Canada, New Zealand
Boehringer Ingelheim

Completed

Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers

Healthy

3

Subscribe